See every side of every news story

Published 3 days ago • loading... • Updated 2 days ago

Patents expiring, what Pfizer, Astrazeneca, Eli Lilly, Merck and more risk

Summary by Vogon Today

From Pfizer to Astrazeneca, passing through Eli Lilly, Merck and other Big Pharma. Starting this year, the patents of some of the best-selling drugs will expire. This is how much the arrival of generic versions on the market will weigh on pharmaceutical companies. Facts, names and numbers Not just weight loss drugs. Also seeing their patents expire soon are 8 key drugs produced by some of the largest pharmaceutical companies, who may have to dea…

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

2 Articles

All

Left

Center

Right

AstraZeneca’s cholesterol pill is set for Phase 3, but lags behind Merck rival

AstraZeneca has great ambitions for its mid-stage oral cholesterol drug, believing that it could reach peak sales of more than $5 billion. Positive data presented Monday at the American College of Cardiology meeting bring that ...

2 days ago

Read Full Article

Patents expiring, what Pfizer, Astrazeneca, Eli Lilly, Merck and more risk

From Pfizer to Astrazeneca, passing through Eli Lilly, Merck and other Big Pharma. Starting this year, the patents of some of the best-selling drugs will expire. This is how much the arrival of generic versions on the market will weigh on pharmaceutical companies. Facts, names and numbers Not just weight loss drugs. Also seeing their patents expire soon are 8 key drugs produced by some of the largest pharmaceutical companies, who may have to dea…

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources2

Leaning Left0Leaning Right0Center0Last Updated2 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Vogon Today broke the news in 3 days ago on Sunday, March 30, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content. Stay informed with comprehensive global news coverage all in one place. Subscribe now to compare different perspectives, identify biases, and stay ahead of algorithms